A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis

Although ursodeoxycholic acid (UDCA) is a first‐line treatment for primary biliary cholangitis (PBC), 20%‐30% of patients with PBC exhibit an incomplete response to UDCA. Recently, the UDCA Response Score was proposed for predicting response to UDCA using pretreatment parameters in patients with PBC. We aimed to validate the UDCA Response Score in Japanese patients with PBC.

• Publication year

  2020

• Venue

  Liver international (Print)

• Publication date

  2020-05-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/liv.14534PMID 32438508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging novel treatments for autoimmune liver diseases

  2019cited by this paper
• Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

  2019cited by this paper
• Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis

  2019cited by this paper
• Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

  2018cited by this paper
• A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

  2018cited by this paper
• EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

  2017cited by this paper
• Primary biliary cholangitis: a comprehensive overview

  2017cited by this paper
• A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

  2016cited by this paper
• Guidelines for the management of primary biliary cirrhosis

  2014cited by this paper
• AUTOIMMUNE , CHOLESTATIC , AND BILIARY DISEASE Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid

  2013cited by this paper
• Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

  2013cited by this paper
• Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

  2010cited by this paper
• Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

  2009cited by this paper
• Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

  2008cited by this paper
• Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

  2006cited by this paper
• Primary biliary cirrhosis

  1998cited by this paper
• Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

  1987cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper
• University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

  year unknowncited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Primary Biliary Cirrhosis

  year unknowncited by this paper

• Evolving paradigms in primary biliary cholangitis: from molecular mechanisms to personalized therapeutics with seladelpar, elafibranor, and beyond

  2025cites this paper
• Primary biliary cholangitis.

  2024cites this paper
• Predicting Risk in Primary Biliary Cholangitis

  2023cites this paper
• Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study

  2023cites this paper
• Primary biliary cholangitis: Epidemiology, prognosis, and treatment

  2023cites this paper
• Risk Stratification in Primary Biliary Cholangitis

  2023cites this paper
• APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

  2022cites this paper
• Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms

  2022cites this paper
• 5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance.

  2021cites this paper
• External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis

  2021cites this paper
• Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.

  2021cites this paper
• Primary Biliary Cholangitis

  2020cites this paper
• The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis

  2020cites this paper
• Current understanding of primary biliary cholangitis

  2020cites this paper
• Primary biliary cholangitis.

  2020cites this paper
• Prognostic scores in primary biliary cholangitis

  2020cites this paper
• Primary biliary cholangitis

  2020cites this paper
• The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis

  2020cites this paper